T-MAXIMUM Presents B7-H3 CAR-T Therapy for Brain Metastases
T-MAXIMUM presented early data on its B7-H3 allogeneic CAR-T therapy for brain metastases at the WCLC conference. Initial findings suggest potential for treating systemic diseases targeting the brain.
T-MAXIMUM presented early data on its B7-H3 allogeneic CAR-T therapy for brain metastases at the World Conference on Lung Cancer (WCLC) this week.
The presentation focused on the evolving landscape of B7-H3-targeted therapies, particularly in small cell lung cancer. The research is now exploring the application of this approach to systemic diseases, specifically addressing the challenge of treating the brain, where drug delivery can be limited.
B7-H3 is a protein expressed on various cancer types, making it a target for new therapeutic strategies. Allogeneic CAR-T therapy, which uses donor-derived T-cells, offers a potential advantage in terms of accessibility and speed compared to autologous CAR-T, which requires patient-specific cell collection and manufacturing.
These initial findings highlight B7-H3's role in advancing cancer treatment. T-MAXIMUM's work aims to address the unmet need for effective treatments for brain metastases, offering new hope for patients with these challenging conditions.